Grant: Collaborative Research and Development Grants
University of Prince Edward Island
$161,400.00
Responses of sea lice to novel parasiticides and their differing modes of action
FY 2016-17
Summary
Salmon lice, Lepeophtheirus salmonis (Copepoda: Caligidae), are important ectoparasites both ecologically and economically. Sea lice cause multi-million dollar losses to the marine salmon aquaculture industry each year, and can negatively impact wild stocks of salmonids as well. Over the past two decades perhaps the greatest emerging issue with respect to sea lice has been the development of resistance to chemical treatment. All of the major salmon producing countries (i.e. Norway, Scotland, Chile, Canada, etc.) have observed declines in efficacy of anti-parasitic treatments, and development of resistant strains of lice. Within Eastern Canada, the major impact has been observed in reduced efficacy of emamectin benzoate (Jones et al, 2012), and recently our research group has identified louse gene clusters associated with reduced efficacy of this drug in Pacific Canada (British Columbia). Currently there is a lack of compounds of different classes and different modes of action for treatment of sea lice in Canada, however, use of organophosphates and pyrethroids occurs in other countries, and have also exhibited issues with resistance development. In order to target this gap in effective management tools for sea lice globally, Elanco Animal Health has developed an in-feed treatment (lufenuron) against sea lice to be administered at the hatchery and provide long-term protection of salmon against infection at sea. Lufenuron is currently undergoing clinical trials in Canada, Chile and Norway, to determine the protection period conferred by the developmental product. It is the goal of the current work to identify the mode of action (MoA) of lufenuron in sea lice and potential future mechanisms of drug resistance. This will be achieved through (1) Determining physiological impacts of lufenuron on the life cycle of L. salmonis, (2) Identifying genes/genotypes associated with resistance to lufenuron in L. salmonis populations, and (3) Developing a lufenuron-specific modelling framework to identify genetic interactions in different farming regions.
Program
Collaborative Research and Development Grants
Recipient
Location
Prince Edward Island, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
499789-2016
Name nom
Fast, Mark
Department département
Pathology and Microbiology
Organization id
88
Institution établissement
University of Prince Edward Island
Province en
Prince Edward Island
Province fr
?le-du-Prince-Édouard
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
161400
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
106
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Aquaculture
Area of application fr
Aquiculture
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Veterinary sciences
Research subject fr
Médecine vétérinaire
Partie
1
Nb partie
2
Application title
Responses of sea lice to novel parasiticides and their differing modes of action
Keyword
NSERC
Application summary
Salmon lice, Lepeophtheirus salmonis (Copepoda: Caligidae), are important ectoparasites both ecologically and economically. Sea lice cause multi-million dollar losses to the marine salmon aquaculture industry each year, and can negatively impact wild stocks of salmonids as well. Over the past two decades perhaps the greatest emerging issue with respect to sea lice has been the development of resistance to chemical treatment. All of the major salmon producing countries (i.e. Norway, Scotland, Chile, Canada, etc.) have observed declines in efficacy of anti-parasitic treatments, and development of resistant strains of lice. Within Eastern Canada, the major impact has been observed in reduced efficacy of emamectin benzoate (Jones et al, 2012), and recently our research group has identified louse gene clusters associated with reduced efficacy of this drug in Pacific Canada (British Columbia). Currently there is a lack of compounds of different classes and different modes of action for treatment of sea lice in Canada, however, use of organophosphates and pyrethroids occurs in other countries, and have also exhibited issues with resistance development. In order to target this gap in effective management tools for sea lice globally, Elanco Animal Health has developed an in-feed treatment (lufenuron) against sea lice to be administered at the hatchery and provide long-term protection of salmon against infection at sea. Lufenuron is currently undergoing clinical trials in Canada, Chile and Norway, to determine the protection period conferred by the developmental product. It is the goal of the current work to identify the mode of action (MoA) of lufenuron in sea lice and potential future mechanisms of drug resistance. This will be achieved through (1) Determining physiological impacts of lufenuron on the life cycle of L. salmonis, (2) Identifying genes/genotypes associated with resistance to lufenuron in L. salmonis populations, and (3) Developing a lufenuron-specific modelling framework to identify genetic interactions in different farming regions.